GlaxoSmithKline (GB:GSK) has released an update.
GlaxoSmithKline has announced promising results from their SWIFT-1 and SWIFT-2 phase III clinical trials of depemokimab, showing a 54% reduction in severe asthma exacerbations over a year. The biologic, intended for severe asthma patients with type 2 inflammation, is administered once every six months and has also shown to significantly reduce hospitalizations. These findings, also published in the New England Journal of Medicine, are set to inform future regulatory filings as depemokimab is not yet approved for use.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.
